Clinical Trial

Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)

Study acronym: SOUNDTRACK-C1
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the therapeutic benefit and safety of subcutaneous (SC) Surovatamig monotherapy as consolidation therapy in patients with Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) with unmutated IGHV (uIGHV).
Protocol Amendment History 4 changes
critical Recruitment opened 2026-06-02
notable Trial sites expanded: 13 -> 30 locations 2026-06-02
notable Primary completion moved earlier: 2032-11-29 -> 2031-08-29 2026-06-02
minor Completion moved earlier: 2033-08-29 -> 2032-04-05 2026-06-02
Trial Details
NCT Number NCT07509151
Lead Sponsor AstraZeneca
Collaborators: Parexel
Conditions Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV
Enrollment 420 participants
Start Date 2026-05-05
Primary Completion 2031-08-29 (estimated)
Study Completion 2032-04-05 (estimated)
Updated on ClinicalTrials.gov 2026-08-10